GlycoNex

GlycoNex Current Liabilities

The Current Liabilities of GlycoNex (4168.TWO) as of Nov 4, 2026 is 849,000.00 TWD. In the previous year, Current Liabilities was 238.58 M TWD — a change of -99.64% (lower).

Current Liabilities

849,000.00TWD

YoY

-99.64%

Last updated:

Current Liabilities of GlycoNex is 2025 849,000.00 TWD. Current Liabilities of GlycoNex was 2024 238.58 M TWD. It decreases by -99.64% lower compared to the previous year.

The GlycoNex Current Liabilities history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Current Liabilities
Date
Current Liabilities
Jan 1, 2018
19.71 M TWD
Jan 1, 2019
5.15 M TWD
Jan 1, 2020
26.47 M TWD
Jan 1, 2021
43.09 M TWD
Jan 1, 2022
60.04 M TWD
Jan 1, 2023
302.15 M TWD
Jan 1, 2024
238.58 M TWD
Jan 1, 2025
849,000.00 TWD
The GlycoNex Current Liabilities history
YEARCurrent LiabilitiesYoY
849,000.00TWD-99.64%
238.58 MTWD-21.04%
302.15 MTWD+403.25%
60.04 MTWD+39.34%
43.09 MTWD+62.77%
26.47 MTWD+414.54%
5.15 MTWD-73.90%
19.71 MTWD+252.32%
5.59 MTWD-87.50%
44.77 MTWD-2.18%
45.77 MTWD+1.43%
45.12 MTWD+270.33%
12.18 MTWD-60.90%
31.17 MTWD-2.58%
31.99 MTWD-8.65%
35.02 MTWD+41.34%
24.78 MTWD+37.85%
17.97 MTWD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

GlycoNex Stock analysis

What does GlycoNex do? GlycoNex, Inc. develops anti-cancer monoclonal antibodies and bio-similar drugs, offering licensing for monoclonal antibody targets and carbohydrate antigen and protein drug services. The company targets domestic and Asian markets, distributing its products through these regions. Revenue comes from drug development, licensing agreements, and service provision for antibody targets and related biotech solutions. GlycoNex focuses on anti-cancer monoclonal antibody new drugs and bio-similar drugs, with services including carbohydrate antigen and protein drug related offerings. The firm serves domestic and overseas markets in Asia, generating income from product development, licensing, and specialized biotech services. Its business model relies on developing and commercializing innovative cancer treatments and related services in key Asian markets. The company's revenue streams include the development of anti-cancer monoclonal antibody new drugs, bio-similar drugs, and the licensing of monoclonal antibody targets. Services related to carbohydrate antigen and protein drug solutions are also part of the business, distributed across domestic and Asian markets to generate income from pharmaceutical innovation and biotech service contracts. GlycoNex is one of the most popular companies on Eulerpool.

Frequently Asked Questions about GlycoNex stock

Current Liabilities of GlycoNex is 849,000.00 TWD in 2025.

Current Liabilities of GlycoNex changed from 238.58 M TWD to 849,000.00 TWD, representing a -99.64% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Current Liabilities GlycoNex since 2006 – with annual values, charts, and detailed analysis.

Current liabilities are obligations due within one year, including accounts payable, short-term debt, and accrued expenses.

Current Liabilities's TWD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Current Liabilities's GlycoNex historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Balance Sheet — GlycoNex

All Key Metrics — GlycoNex